ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered Blog ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…CertaraJuly 23, 2025
MIDD can ease pediatric & rare disease drug loss in Japan Blog MIDD can ease pediatric & rare disease drug loss in Japan Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…CertaraJuly 8, 2025
Accelerating Oncology Drug FDA RTOR Submission with Project Management Services Case Study Accelerating Oncology Drug FDA RTOR Submission with Project Management Services Discover how Certara’s dedicated project management and pharmacometric support helped an emerging biotech company fast-track…CertaraJuly 2, 2025
5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address Blog 5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address June 30, 2025 Drug development is increasingly defined by its complexity. Teams must navigate rising…CertaraJune 30, 2025
How Model-informed drug development rescue projects from a risky situation Case Study How Model-informed drug development rescue projects from a risky situation Discover how Certara’s integrated approach to model-informed drug development helps clients navigate regulatory challenges, achieve…CertaraJune 26, 2025
Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning Publication Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully…Danielle PillsburyJune 19, 2025
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara On-Demand Webinar From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…CertaraJune 18, 2025
Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis On-Demand Webinar Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis CertaraJune 11, 2025
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer Publication Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…CertaraJune 8, 2025
Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance On-Demand Webinar Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…CertaraMay 23, 2025